DIPG-21. GENOMIC LANDSCAPE OF THE FIRST 100 TUMORS REGISTERED IN THE BIOLOGICAL MEDICINE FOR DIPG ERADICATION (BIOMEDE) TRIAL

BACKGROUND: Genomic analyses of DIPG have been so far mostly performed on autopsy samples or in retrospective studies. In the frame of the BIOMEDE randomized trial of three targeted therapies (erlotinib, everolimus, dasatinib) based on three biomarkers (EGFR, PTEN and PDGFRA respectively), a systema...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Neuro Oncol
Autores principales: Castel, David, Barret, Emilie, Picot, Stephanie, Plessier, Alexandre, Le Dret, Ludivine, Nysom, Karsten, Huybrechts, Sophie, Capolino, Perrine, Le Deley, Marie-Cecile, Vassal, Gilles, Puget, Stephanie, Varlet, Pascale, Grill, Jacques, Debily, Marie-Anne
Formato: Artigo
Lenguaje:Inglês
Publicado: Oxford University Press 2017
Materias:
Abstracts
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5475015/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox083.036
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares